The MET protooncogene encodes the receptor tyrosine kinase c-MET (MET). Aberrant
activation of MET signaling occurs in a subset of advanced malignancies, including gastric …

Chemotherapy has become the global standard treatment for patients with metastatic or
unresectable gastric cancer (GC), although outcomes remain unfavorable. Many molecular …

Our aim was to investigate both the prevalence of MET amplification in gastric cancer as well
as the potential of this genetic alteration to serve as a therapeutic target in gastric cancer …

Gastric cancer remains a disease with a dismal prognosis. Extensive efforts to find
targetable disease drivers in gastric cancer were implemented to improve patient outcomes …

The MET/hepatocyte growth factor (HGF) signaling pathway plays important roles in
oncogenesis and tumor progression in a variety of human cancers. MET/HGF drives an …

The MET oncogene is amplified in a fraction of human gastric carcinoma cell lines, with
consequent overexpression and constitutive activation of the corresponding protein product …

The Met receptor tyrosine kinase is activated or genetically amplified in some gastric
cancers, but resistance to small-molecule inhibitors of Met often emerges in patients. We …

Aberrant activation of the HGF/MET signaling axis has been strongly implicated in the
malignant transformation and progression of gastroesophageal cancer (GEC). MET receptor …

Despite significant improvements in systemic chemotherapy over the last two decades, the
prognosis of patients with advanced gastric and gastroesophageal junction …

Background: MET, the receptor for hepatocyte growth factor, has been proposed as a
therapeutic target in gastric cancer. This study assessed the incidence of MET expression …